RENSCHLER MARKUS MD 4
4 · Cyteir Therapeutics, Inc. · Filed Dec 23, 2022
Insider Transaction Report
Form 4
RENSCHLER MARKUS MD
DirectorSee Remarks
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2022-12-21−106,345→ 0 totalExercise: $1.03Exp: 2028-12-10→ Common Stock (106,345 underlying) - Exercise/Conversion
Common Stock
2022-12-21$1.03/sh+106,345$109,535→ 948,299 total - Exercise/Conversion
Common Stock
2022-12-21$1.20/sh+30,437$36,524→ 978,736 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-12-21−30,437→ 32,973 totalExercise: $1.20Exp: 2030-02-24→ Common Stock (30,437 underlying)
Footnotes (3)
- [F1]Due to rounding in connection with the Issuer's reverse stock split during its initial public offering, the exercise price and the number of securities underlying this option were immaterially incorrect as reported on the Reporting Person's Form 3 filing on June 17, 2021. These numbers have been corrected in this Form 4.
- [F2]The option vested at a rate of 18,334 shares per month at the end of each successive one-month period beginning January 3, 2019, for 40 months, and at a rate of 14,703 shares per month at the end of the 41st month, at which point the option was fully vested.
- [F3]The option vests as to 1/48th of the underlying shares of common stock on February 1, 2020, and at the same rate at the end of each successive one-month period following such date until the fourth anniversary of such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.